reiter ow companion anim
led growth deliv rais pt
report revenu vs consensu adj ebitda
vs consensu adj dilut ep vs consensu
manag rais fy revenu guidanc
adjust dilut ep guid result reaffirm
key tenet invest thesi strong growth potenti ca driven
derm parasiticid abaxi recent launch expand market key
product like apoqel cytopoint simparica trio revolut stronghold abil
weather african swine flu asf pressur diversifi portfolio see june
product continu deliv drive companion anim growth report
ca revenu vs consensu ca grew faster
us revenu oper growth vs driven derm parasiticid
includ simparica stronghold abaxi acquisit contribut addit
quarter total ca segment growth exclud fx impact
poultri strength offset asf pressur swine manag cite latest estim
swine china impact diseas expect
revenu impact compani anticip
offset growth market includ brazil eu expect minim
addit revenu due slow natur increas livestock product
valuat premium multipl sustain rais pt
use price-to-earnings multipl higher end histor trade rang
stabl defens growth risk downsid fx headwind higher-than-
anticip gener threat global macro slowdown increas
incid asf upsid acceler global growth value-ad
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight ow driven
new launch companion anim health
greater thrust toward biolog drug
unmet need chronic diseas pet also
expect continu effici alloc
capit done past value-ad
strong global growth faster anticip margin
expans earlier launch symparica trio valu
weak integr abaxi delay launch
symparica trio greater anticip competit
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
report result ahead
consensu driven strong
growth companion
anim segment improv
rais pt use price-to-earnings multipl
valu higher end histor trade rang stabl defens
growth expect multipl stay intact compani continu deliv strong
revenu earn growth risk thesi downsid fx headwind usd
strength higher-than-anticip gener threat global macro slowdown
increas incid asf upsid acceler global growth value-
rais month pt
companion gross ep varianc vs consvari vs barclaysp multiplehistor average multipl base per share barclay zoeti inc
balaji prasad md herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
